Acumen Pharmaceuticals
ABOS
71 hedge funds and large institutions have $75.2M invested in Acumen Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 13 increasing their positions, 22 reducing their positions, and 8 closing their positions.
50% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 8
23% more capital invested
Capital invested by funds: $61.1M → $75.2M (+$14.1M)
3% more funds holding
Funds holding: 69 → 71 (+2)
0.12% less ownership
Funds ownership: 58.99% → 58.87% (-0.12%)
41% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$315K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$149K |
| 3 |
PFS
Prospera Financial Services
Dallas,
Texas
|
+$99.2K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$98.3K |
| 5 |
QC
Quadrature Capital
London,
United Kingdom
|
+$97.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$320K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$295K |
| 3 |
Jane Street
New York
|
-$129K |
| 4 |
Two Sigma Investments
New York
|
-$112K |
| 5 |
Goldman Sachs
New York
|
-$58.1K |
ABOS Hedge Fund Activity: Q4 2025 in Review
71 of the 8,225 institutional investors tracked by Wall St. Rank reported a position in Acumen Pharmaceuticals (ABOS) for Q4 2025, worth a combined $75.2M — up 23% from $61.1M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ABOS positions and 8 closed out — a net gain of 4 holders — while 13 added to existing stakes and 22 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $315K. The largest seller was Renaissance Technologies, cutting an estimated $320K.
- 71 institutional investors held Acumen Pharmaceuticals (ABOS) as of Q4 2025, up from 69 in Q3 2025.
- Funds reported $75.2M of Acumen Pharmaceuticals stock for Q4 2025, up 23% quarter-over-quarter.
- 12 funds opened new Acumen Pharmaceuticals positions in Q4 2025 and 8 closed out, a net change of +4 holders.
- The largest Acumen Pharmaceuticals buyer in Q4 2025 was Susquehanna International Group, an estimated $315K added.
- The largest Acumen Pharmaceuticals seller in Q4 2025 was Renaissance Technologies, an estimated $320K sold.
Based on aggregated 13F filings for Q4 2025.